MIAMI, FL USA (UroToday.com) - The efficacy of fesoterodine was assessed in patients with refractory OAB symptoms after treatment for BPH. This was a single-center pilot study of 18 male patients > 40 years of age who had bladder outlet obstruction, treated surgically, at least one month prior.

Primary endpoint was a change in International Prostate Symptom Score (IPSS) with secondary endpoints maximum urine flow rates and PVR. Fesoterodine significantly improved IPSS compared to baseline. Adverse events were: 3 (17%) patients had constipation, 1 (6%) with vision change, and 2 (11%) with dry mouth.

sufu xPresented by Lily C. Wang, Bilal Chughtai, Asha E. Jamzadeh, Richard K. Lee, Steven A. Kaplan, and Alexis E. Te at the Society of Urodynamics, Female Pelvic Medicine and Urogenital Reconstruction (SUFU) Winter Meeting - February 25 - March 1, 2014 - Doral Golf Resort and Spa - Miami, Florida USA

 

Reported for UroToday.com by Diane K. Newman, DNP, FAAN, BCB-PMD

 

Calendar
Upcoming urology industry events
April 27-29, 2018 / European Society for Medical Oncology Update for Practising Oncologists
European Society for Medical Oncology Update for Practising Oncologists
May 14, 2018 / InterContinental Mark Hopkins Hotel
SITC Cancer Immune Responsiveness Workshop
May 16-17, 2018 / InterContinental Mark Hopkins Hotel
SITC Immuno-Oncology Biomarkers: State of the Art Workshop
May 17, 2018 / Moscone Convention Center North/South, San Francisco, CA
SAU 2018 Annual Meeting at the AUA
Journals
Print publications focusing on urological cancer treatments through original commentary & articles

Everyday Urology™ - Oncology Insights

From the Editor

Prostate Cancer and Prostatic Diseases

From the Editor